• Edap TMS annual report for fiscal year ended Dec. 31, 2025 outlined accelerating shift toward Focal One robotic HIFU as core growth platform, supported by higher system placements and rising procedure volumes, led by US demand for organ-sparing prostate cancer treatment.
• Rollout of next-generation Focal One i highlighted as key product upgrade, designed to integrate advanced imaging such as PSMA-PET to improve targeting and standardize workflows.
• Regulatory progress broadened platform runway, including CE Mark in March 2025 for treatment of posterior deep infiltrating endometriosis, positioning HIFU as non-invasive alternative to complex surgery.
• US clearance in November 2025 covered latest evolution of Focal One, adding next-generation ultrasound imaging intended to support future AI-driven visualization and treatment evaluation.
• Strategy update flagged reduced emphasis on legacy, non-core activities to concentrate investment on higher-growth HIFU opportunities, with management pointing to continued momentum into 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edap TMS SA published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.